Nanotechnology Now

Our NanoNews Digest Sponsors





Heifer International

Wikipedia Affiliate Button


DHgate

Home > Press > Spectrum Pharmaceuticals Acquires Full Rights and Intellectual Property for RenaZorb® for All Fields of Use

Abstract:
Spectrum Pharmaceuticals, Inc. (NasdaqGM:SPPI), a commercial-stage biotechnology company with a primary focus in oncology, today announced that it has acquired 100% rights to RenaZorb® (a family of compounds represented by SPI-014, also known as RZB-014), a lanthanum-based nanotechnology compound with potent and selective phosphate binding properties, for all human and non-human indications.

Spectrum Pharmaceuticals Acquires Full Rights and Intellectual Property for RenaZorb® for All Fields of Use

Irvine, CA | Posted on September 7th, 2009

"While focused on the oncology field, we remain opportunistic with our other value-driving assets such as RenaZorb, a drug candidate with the potential to reduce dosage burden for chronic kidney disease patients and enable more effective management of their disease," said Rajesh C. Shrotriya, MD, Chairman, Chief Executive Officer, and President of Spectrum Pharmaceuticals. "Having full rights to this selective and potent nanotechnology-based drug candidate will facilitate our development and partnering strategy for this asset."

In 2005, the Company acquired the worldwide license to develop RenaZorb for all human therapeutic uses from Altair Nanotechnologies. Today's acquisition includes all uses and thus provides full rights, and intellectual property, for the asset. In consideration for the license, Spectrum will pay to Altair a total of $750,000 in restricted common stock.

"Given the importance of effectively controlling serum phosphate levels for patients with chronic kidney disease, there has been significant recent activity to extend the use of phosphate binding medications to a wider proportion of the 26 million Americans currently suffering with CKD," said Amar Singh, Chief Commercial Officer. "Given this activity, and the limitations of existing phosphate binding medications, the market opportunity for new safe and effective phosphate binding medications has significantly increased not only in the U.S. but in other major pharmaceutical markets such as Europe, China, and Japan. Having full title to this asset allows us to maximize the value of this opportunity."

Forward-looking statement - This press release may contain forward-looking statements regarding future events and the future performance of Spectrum Pharmaceuticals that involve risks and uncertainties that could cause actual results to differ materially. These statements include but are not limited to statements that relate to our business and its future, Spectrum's ability to identify, acquire, develop and commercialize a broad and diverse pipeline of late-stage clinical and commercial products, establishing a commercial organization for our approved drugs, continuing to build our team, leveraging the expertise of partners around the world to assist us in the execution of our strategy, RenaZorb's potential to reduce dosage burden for chronic kidney disease patients and enable more effective management of their disease, that having full title to RenaZorb allows us to maximize the value of this opportunity and any statements that relate to the intent, belief, plans or expectations of Spectrum or its management, or that are not a statement of historical fact. Risks that could cause actual results to differ include the possibility that our existing and new drug candidates, may not prove safe or effective, the possibility that our existing and new drug candidates may not receive approval from the FDA, and other regulatory agencies in a timely manner or at all, the possibility that our existing and new drug candidates, if approved, may not be more effective, safer or more cost efficient than competing drugs, the possibility that our efforts to acquire or in-license and develop additional drug candidates may fail, our lack of revenues, our limited marketing experience, our dependence on third parties for clinical trials, manufacturing, distribution and quality control and other risks that are described in further detail in the Company's reports filed with the Securities and Exchange Commission. We do not plan to update any such forward-looking statements and expressly disclaim any duty to update the information contained in this press release except as required by law.

SPECTRUM PHARMACEUTICALS, INC.® and RenaZorb® are registered trademarks of Spectrum Pharmaceuticals, Inc. TURNING INSIGHTS INTO HOPE™ and the Spectrum Pharmaceutical logos are trademarks owned by Spectrum Pharmaceuticals, Inc.

####

About Spectrum Pharmaceuticals
Spectrum Pharmaceuticals is a commercial-stage biotechnology company with a focus in oncology. The Company’s strategy is comprised of acquiring and developing a broad and diverse pipeline of late-stage clinical and commercial products; establishing a commercial organization for its approved drugs; continuing to build a team with people who have demonstrated skills, passion, commitment and have a track record of success in its areas of focus; and, leveraging the expertise of partners around the world to assist it in the execution of its strategy.

About RenaZorb®

RenaZorb, or SPI-014, is a non-aluminum, non-polymer, non-calcium, lanthanum-based nanotechnology with highly potent and selective phosphate binding properties, for the potential treatment via oral administration, of hyperphosphatemia, (high phosphate levels in the blood), in patients with chronic kidney disease (CKD). Hyperphosphatemia in Stage 5 CKD, also known as end-stage renal disease (ESRD), can lead to significant bone disease (including pain and fractures), secondary hyperthyroidism in renal sufficiency, cardiovascular disease, and is independently associated with increased mortality. Currently marketed therapies for treating hyperphosphatemia include polymer-based and lanthanum-based phosphate binders, aluminum-based phosphate binders, and calcium-based phosphate binders. According to the United States Renal Data System (USRDS), over the last 20 years, the number of patients with ESRD in the US has grown 4-fold. By 2010 there will be an estimated 661,330 patients with ESRD.

For more information, please click here

Contacts:
Spectrum Pharmaceuticals, Inc. Russell Skibsted Sr. Vice President & Chief Business Officer 949-788-6700x234 or Paul Arndt Senior Manager, Investor Relations 949-788-6700x216

Copyright © Spectrum Pharmaceuticals

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Thin films offer promise for ferroelectric devices: Researchers at Tokyo Institute of Technology demystify the ferroelectric properties observed in hafnium-oxide-based thin films, revealing a potentially useful device material August 3rd, 2015

Harris & Harris Group Portfolio Company, HZO, Announces Partnerships with Dell and Motorola August 1st, 2015

Advances and Applications in Biosensing, Sensor Power, and Sensor R&D to be Covered at Sensors Global Summit August 1st, 2015

Kalam: versatility personified August 1st, 2015

Nanomedicine

Gold-diamond nanodevice for hyperlocalised cancer therapy: Gold nanorods can be used as remote controlled nanoheaters delivering the right amount of thermal treatment to cancer cells, thanks to diamond nanocrystals used as temperature sensors August 1st, 2015

Heating and cooling with light leads to ultrafast DNA diagnostics July 31st, 2015

Take a trip through the brain July 30th, 2015

Sol-gel capacitor dielectric offers record-high energy storage July 30th, 2015

Announcements

Thin films offer promise for ferroelectric devices: Researchers at Tokyo Institute of Technology demystify the ferroelectric properties observed in hafnium-oxide-based thin films, revealing a potentially useful device material August 3rd, 2015

Transparent, electrically conductive network of encapsulated silver nanowires: A novel electrode for optoelectronics August 1st, 2015

Harris & Harris Group Portfolio Company, HZO, Announces Partnerships with Dell and Motorola August 1st, 2015

Advances and Applications in Biosensing, Sensor Power, and Sensor R&D to be Covered at Sensors Global Summit August 1st, 2015

Patents/IP/Tech Transfer/Licensing

Quantum networks: Back and forth are not equal distances! July 28th, 2015

Reshaping the solar spectrum to turn light to electricity: UC Riverside researchers find a way to use the infrared region of the sun's spectrum to make solar cells more efficient July 27th, 2015

Smarter window materials can control light and energy July 22nd, 2015

Magnetic nanoparticles could be key to effective immunotherapy: New method moves promising strategy closer to clinical use July 15th, 2015

Nanobiotechnology

Heating and cooling with light leads to ultrafast DNA diagnostics July 31st, 2015

European Technology Platform for Nanomedicine and ENATRANS European Consortium Launch the 2nd edition of the Nanomedicine Award: The Award to be presented at BIO-Europe conference in Munich, November 2015 July 30th, 2015

New computer model could explain how simple molecules took first step toward life: Two Brookhaven researchers developed theoretical model to explain the origins of self-replicating molecules July 28th, 2015

Spintronics: Molecules stabilizing magnetism: Organic molecules fixing the magnetic orientation of a cobalt surface/ building block for a compact and low-cost storage technology/ publication in Nature Materials July 25th, 2015

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project